These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3005775)

  • 1. Ergot alkaloids and central monoaminergic receptors.
    Goldstein M
    J Pharmacol; 1985; 16 Suppl 3():19-24. PubMed ID: 3005775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR; Creese I
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
    Goldstein M; Lew JY; Hata F; Lieberman A
    Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain.
    Kehr W
    Eur J Pharmacol; 1977 Feb; 41(3):261-73. PubMed ID: 837971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central monoamine synapses as sites of action for ergot drugs.
    Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
    Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic activity of some ergot alkaloid derivatives: relationship to their chemical structure.
    Soskić V; Petrović J; Trajković D; Kidric M
    Pharmacology; 1986; 32(3):157-66. PubMed ID: 2938196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine inhibits a sustained calcium current through activation of alpha adrenergic receptors and a GTP-binding protein in adult rat sympathetic neurons.
    Aguayo LG; Grossie J
    J Pharmacol Exp Ther; 1994 May; 269(2):503-8. PubMed ID: 8182518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors.
    Schurad B; Horowski R; Jähnichen S; Görnemann T; Tack J; Pertz HH
    Life Sci; 2006 Apr; 78(20):2358-64. PubMed ID: 16310806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of neurotransmitter receptor binding by ergot derivatives.
    Hruska RE; Silbergeld EK
    J Neurosci Res; 1981; 6(1):1-11. PubMed ID: 6111611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.
    Goldstein M; Lew JY; Sauter A; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():75-82. PubMed ID: 7395625
    [No Abstract]   [Full Text] [Related]  

  • 13. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain.
    Burt DR; Creese I; Snyder SH
    Mol Pharmacol; 1976 Jul; 12(4):631-8. PubMed ID: 958211
    [No Abstract]   [Full Text] [Related]  

  • 15. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
    Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
    Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
    Newman-Tancredi A; Cussac D; Audinot V; Nicolas JP; De Ceuninck F; Boutin JA; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):805-14. PubMed ID: 12388667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors: subtypes, localization and regulation.
    Creese I; Sibley DR; Leff S; Hamblin M
    Fed Proc; 1981 Feb; 40(2):147-52. PubMed ID: 7007083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the immune response by ergot alkaloids.
    Sterzl J; Rehácek Z; Cudlín J
    Czech Med; 1987; 10(2):90-8. PubMed ID: 2888605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the central nervous system on the action of epinephrine and adrenolytic drugs.
    Thuránszky K
    Arch Int Pharmacodyn Ther; 1966 Jan; 159(1):53-60. PubMed ID: 5918767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.